Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 29;16(7):1346.
doi: 10.3390/cancers16071346.

Risk-Tailoring Radiotherapy for Endometrial Cancer: A Narrative Review

Kristin Hsieh  1 , Julie R Bloom  1 , Daniel R Dickstein  1 , Anuja Shah  1 , Catherine Yu  1 , Anthony D Nehlsen  1 , Lucas Resende Salgado  1 , Vishal Gupta  1 , Manjeet Chadha  1 , Kunal K Sindhu  1
Affiliations
Review

Risk-Tailoring Radiotherapy for Endometrial Cancer: A Narrative Review

Kristin Hsieh et al. Cancers (Basel). .

Abstract

Endometrial cancer is the most common gynecologic cancer in the United States and it contributes to the second most gynecologic cancer-related deaths. With upfront surgery, the specific characteristics of both the patient and tumor allow for risk-tailored treatment algorithms including adjuvant radiotherapy and systemic therapy. In this narrative review, we discuss the current radiation treatment paradigm for endometrial cancer with an emphasis on various radiotherapy modalities, techniques, and dosing regimens. We then elaborate on how to tailor radiotherapy treatment courses in combination with other cancer-directed treatments, including chemotherapy and immunotherapy. In conclusion, this review summarizes ongoing research that aims to further individualize radiotherapy regimens for individuals in an attempt to improve patient outcomes.

Keywords: endometrial cancer; personalized treatment; radiation oncology; radiation-induced toxicities; radiotherapy; risk-tailoring; uterine malignancy.

PubMed Disclaimer

Conflict of interest statement

K.H. is supported by the 2023 ASTRO-AstraZeneca Radiation Oncology Research Training Fellowship Program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The remaining authors declare no conflicts of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Cronin K.A., Lake A.J., Scott S., Sherman R.L., Noone A.-M., Howlader N., Henley S.J., Anderson R.N., Firth A.U., Ma J., et al. Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer. 2018;124:2785–2800. doi: 10.1002/cncr.31551. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer Statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. Int. J. Gynecol. Cancer. 2016;26:2–30. doi: 10.1097/IGC.0000000000000609. - DOI - PMC - PubMed
    1. Key Statistics for Endometrial Cancer. [(accessed on 27 October 2023)]. Available online: https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statist....

LinkOut - more resources